ZNTL advances pivotal Azenosertib ovarian cancer trials with FDA support
Azenosertib is advancing through pivotal trials for platinum-resistant ovarian cancer, citing a robust safety profile and a validated biomarker strategy. The company says FDA alignment is strong and highlights a differentiated oral option.
Azenosertib is advancing through pivotal trials for platinum-resistant ovarian cancer, supported by a robust safety profile, a validated biomarker strategy and strong FDA alignment. The drug targets a significant patient subset, offers a differentiated oral option and is supported by a cash runway into 202…